These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 37635503)
1. A Role of β2-Adrenoreceptor Agonists Related to the Development of Parkinson's Disease. Jung D; Kwak DW; Kim M; Lee WW Neurol India; 2023; 71(4):710-715. PubMed ID: 37635503 [TBL] [Abstract][Full Text] [Related]
2. Use of β2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease. Hopfner F; Wod M; Höglinger GU; Blaabjerg M; Rösler TW; Kuhlenbäumer G; Christensen K; Deuschl G; Pottegård A Neurology; 2019 Jul; 93(2):e135-e142. PubMed ID: 31127070 [TBL] [Abstract][Full Text] [Related]
3. Association between β2-Adrenoreceptor Medications and Risk of Parkinson's Disease: A Meta-Analysis. Chen CL; Wang SY; Chen TC; Chuang CS Medicina (Kaunas); 2021 Sep; 57(10):. PubMed ID: 34684044 [No Abstract] [Full Text] [Related]
4. β2-Adrenoceptor Agonists in Asthma or Chronic Obstructive Pulmonary Disease and Risk of Parkinson's Disease: Nested Case-Control Study. Paakinaho A; Tiihonen M; Koskela H; Koponen M; Tiihonen J; Hartikainen S; Tolppanen AM Clin Epidemiol; 2023; 15():695-705. PubMed ID: 37332323 [TBL] [Abstract][Full Text] [Related]
5. Effects of β2-Adrenergic Agonists on Risk of Parkinson's Disease in COPD: A Population-Based Study. Chen W; Sadatsafavi M; Tavakoli H; Samii A; Etminan M Pharmacotherapy; 2020 May; 40(5):408-415. PubMed ID: 32145705 [TBL] [Abstract][Full Text] [Related]
6. Beta2-adrenoreceptor agonists and long-term risk of Parkinson's disease. Tuominen JA; Bjørnevik K; Romanowska J; Solheim MH; Grydeland TB; Cortese M; Scherzer CR; Riise T; Igland J Parkinsonism Relat Disord; 2023 May; 110():105389. PubMed ID: 37027994 [TBL] [Abstract][Full Text] [Related]
7. β2-Adrenoreceptor Agonists, Montelukast, and Parkinson Disease Risk. Liu B; Svenningsson P; Ludvigsson JF; Lundholm C; Wallin J; Larsson H; Sjölander A; Williams DM; Pedersen NL; Wirdefeldt K Ann Neurol; 2023 May; 93(5):1023-1028. PubMed ID: 36897287 [TBL] [Abstract][Full Text] [Related]
8. Association between use of ß2-adrenergic receptor agonists and incidence of Parkinson's disease: Retrospective cohort analysis. Nadeem H; Zhou B; Goldman D; Romley J PLoS One; 2022; 17(11):e0276368. PubMed ID: 36441791 [TBL] [Abstract][Full Text] [Related]
9. Novel drug delivery systems of β2 adrenoreceptor agonists to suppress SNCA gene expression and mitochondrial oxidative stress in Parkinson's disease management. Sola P; Krishnamurthy P; Chintamaneni PK; Pindiprolu SKSS; Kumari M Expert Opin Drug Deliv; 2020 Aug; 17(8):1119-1132. PubMed ID: 32497457 [TBL] [Abstract][Full Text] [Related]
10. β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's disease. Mittal S; Bjørnevik K; Im DS; Flierl A; Dong X; Locascio JJ; Abo KM; Long E; Jin M; Xu B; Xiang YK; Rochet JC; Engeland A; Rizzu P; Heutink P; Bartels T; Selkoe DJ; Caldarone BJ; Glicksman MA; Khurana V; Schüle B; Park DS; Riise T; Scherzer CR Science; 2017 Sep; 357(6354):891-898. PubMed ID: 28860381 [TBL] [Abstract][Full Text] [Related]
11. β2-adrenoceptor agonists and antagonists and risk of Parkinson's disease. Gronich N; Abernethy DR; Auriel E; Lavi I; Rennert G; Saliba W Mov Disord; 2018 Sep; 33(9):1465-1471. PubMed ID: 30311974 [TBL] [Abstract][Full Text] [Related]
12. β2-adrenoreceptor medications and risk of Parkinson disease. Searles Nielsen S; Gross A; Camacho-Soto A; Willis AW; Racette BA Ann Neurol; 2018 Nov; 84(5):683-693. PubMed ID: 30225948 [TBL] [Abstract][Full Text] [Related]
13. Modifiable risk and protective factors in disease development, progression and clinical subtypes of Parkinson's disease: What do prospective studies suggest? Belvisi D; Pellicciari R; Fabbrini G; Tinazzi M; Berardelli A; Defazio G Neurobiol Dis; 2020 Feb; 134():104671. PubMed ID: 31706021 [TBL] [Abstract][Full Text] [Related]